GSK plc (GSK) ORD GBP0.3125
34.00p
(1.57%)
- Add to watchlist
- Create an alert
- This stock can be held in a
34.00p
(1.57%)
Deal for just £11.95 per trade in
a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
34.00p
(1.57%)
Deal for just £11.95 per trade in
a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
GSK secures Japan and China reviews for two late‑stage liver disease treatments
26 February 2026 07:46
(Sharecast News) - Drugmaker GSK said on Thursday that regulators in Japan and China had accepted two separate new drug applications for review, covering investigational treatments targeting chronic...
-
GSK to acquire Canada's 35Pharma for $950m
25 February 2026 07:10
(Sharecast News) - Drugmaker GSK has agreed to acquire Canadian clinical-stage biopharmaceutical firm 35Pharma for $950m in cash.
-
GSK's Exdensur gets green light from European Commission
17 February 2026 08:31
(Sharecast News) - Drugmaker GSK said on Tuesday that the European Commission has approved its asthma and nasal polyps treatment Exdensur (depemokimab) for two separate indications.
-
China's CDE accepts GSK's regulatory filing for RSV vaccine
10 February 2026 07:49
(Sharecast News) - Drugmaker GSK said on Tuesday that China's Center for Drug Evaluation has accepted its regulatory filing for Arexvy, its recombinant, adjuvanted respiratory syncytial virus vaccine,...
-
JP Morgan raises target price on GSK
9 February 2026 12:41
(Sharecast News) - Analysts at JP Morgan raised their target price on drugmaker GSK to £22.50 on Monday on improving investor perception.
-
Director dealings: GSK chairman raises stake
6 February 2026 15:00
(Sharecast News) - GSK revealed on Friday that non-executive chairman Jonathan Symonds had acquired 2,500 ordinary shres in the FTSE 100-listed drugmaker.
-
EU gives GSK's Nucala green light for use in uncontrolled COPD
6 February 2026 07:45
(Sharecast News) - Drugmaker GSK said on Friday that the European Commission has approved Nucala (mepolizumab) as an add‑on maintenance treatment for adults with uncontrolled COPD characterised by elevated...
-
GSK sees slower sales growth in 2026 as patent loss looms
4 February 2026 07:19
(Sharecast News) - UK pharma giant GSK said turnover growth would slow this financial year as it looked to counter the expiry of an HIV drug patent and a deal with the Trump administration to lower product...
-
GSK to cut up to 350 R&D jobs across UK, US
2 February 2026 17:37
(Sharecast News) - GSK is planning to cut as many as 350 jobs in research & development in the UK and US, it was announced on Monday.
-
Citi starts AstraZeneca at 'buy', takes 'neutral' stance on GSK
27 January 2026 11:36
(Sharecast News) - Analysts at Citi initiated coverage of AstraZeneca and GSK on Tuesday, taking a bullish stance on the former but a more cautious view on the latter.
-
GSK vaccine given green light for all adults in Europe
26 January 2026 07:18
(Sharecast News) - The European Commission has approved GSK's respiratory syncytial virus (RSV) vaccine for use in all adults, the drugs giant announced on Monday.
-
GSK to snap up Rapt Therapeutics in $2.2bn deal
20 January 2026 07:57
(Sharecast News) - British drugs giant GSK has agreed to buy Rapt Therapeutics in a $2.2bn deal, it was announced on Tuesday, sending shares in the American allergy specialist soaring.
Company announcements Announcements
-
Transaction in Own Shares
27 February 2026 07:00
GSK
-
Linerixibat accepted for priority review in China
26 February 2026 07:05
GSK
-
Bepirovirsen accepted for Japan regulatory review
26 February 2026 07:00
GSK
-
Transaction in Own Shares
26 February 2026 07:00
GSK
-
Director/PDMR Shareholding
25 February 2026 16:54
GSK
-
Director/PDMR Shareholding
25 February 2026 15:30
GSK
-
GSK enters agreement to acquire 35Pharma
25 February 2026 07:00
GSK
-
Transaction in Own Shares
25 February 2026 07:00
GSK
-
Director/PDMR Shareholding
24 February 2026 15:30
GSK
-
Transaction in Own Shares
24 February 2026 07:00
GSK
-
Transaction in Own Shares
23 February 2026 07:00
GSK
-
Director/PDMR Shareholding
20 February 2026 15:30
GSK
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2026. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.